198 related articles for article (PubMed ID: 27628328)
41. EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases.
Cousineau I; Belmaaza A
Mol Genet Genomics; 2011 Apr; 285(4):325-40. PubMed ID: 21409565
[TBL] [Abstract][Full Text] [Related]
42. Genetic alterations of CCND1 and EMSY in breast cancers.
Kirkegaard T; Nielsen KV; Jensen LB; Campbell FM; Müller S; Tovey SM; Brown S; Cooke TG; Bartlett JM
Histopathology; 2008 May; 52(6):698-705. PubMed ID: 18393977
[TBL] [Abstract][Full Text] [Related]
43. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer.
Basham VM; Lipscombe JM; Ward JM; Gayther SA; Ponder BA; Easton DF; Pharoah PD
Breast Cancer Res; 2002; 4(1):R2. PubMed ID: 11879560
[TBL] [Abstract][Full Text] [Related]
44. Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.
Sun J; Meng H; Yao L; Lv M; Bai J; Zhang J; Wang L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Clin Cancer Res; 2017 Oct; 23(20):6113-6119. PubMed ID: 28724667
[No Abstract] [Full Text] [Related]
45. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
de la Hoya M; Osorio A; Godino J; Sulleiro S; Tosar A; Perez-Segura P; Fernandez C; Rodríguez R; Díaz-Rubio E; Benítez J; Devilee P; Caldés T
Int J Cancer; 2002 Feb; 97(4):466-71. PubMed ID: 11802208
[TBL] [Abstract][Full Text] [Related]
46. Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa.
Staff S; Isola JJ; Johannsson O; Borg A; Tanner MM
Br J Cancer; 2001 Oct; 85(8):1201-5. PubMed ID: 11710835
[TBL] [Abstract][Full Text] [Related]
47. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer.
Chappuis PO; Nethercot V; Foulkes WD
Semin Surg Oncol; 2000 Jun; 18(4):287-95. PubMed ID: 10805950
[TBL] [Abstract][Full Text] [Related]
48. High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history.
Csokay B; Udvarhelyi N; Sulyok Z; Besznyak I; Ramus S; Ponder B; Olah E
Cancer Res; 1999 Mar; 59(5):995-8. PubMed ID: 10070953
[TBL] [Abstract][Full Text] [Related]
49. Expression of EMSY, a novel BRCA2-link protein, is associated with lymph node metastasis and increased tumor size in breast carcinomas.
Madjd Z; Akbari ME; Zarnani AH; Khayamzadeh M; Kalantari E; Mojtabavi N
Asian Pac J Cancer Prev; 2014; 15(4):1783-9. PubMed ID: 24641409
[TBL] [Abstract][Full Text] [Related]
50. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.
Frank TS; Deffenbaugh AM; Reid JE; Hulick M; Ward BE; Lingenfelter B; Gumpper KL; Scholl T; Tavtigian SV; Pruss DR; Critchfield GC
J Clin Oncol; 2002 Mar; 20(6):1480-90. PubMed ID: 11896095
[TBL] [Abstract][Full Text] [Related]
51. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.
Lehrer S; Fodor F; Stock RG; Stone NN; Eng C; Song HK; McGovern M
Br J Cancer; 1998 Sep; 78(6):771-3. PubMed ID: 9743298
[TBL] [Abstract][Full Text] [Related]
52. The molecular genetic make-up of male breast cancer.
Moelans CB; de Ligt J; van der Groep P; Prins P; Besselink NJM; Hoogstraat M; Ter Hoeve ND; Lacle MM; Kornegoor R; van der Pol CC; de Leng WWJ; Barbé E; van der Vegt B; Martens J; Bult P; Smit VTHBM; Koudijs MJ; Nijman IJ; Voest EE; Selenica P; Weigelt B; Reis-Filho JS; van der Wall E; Cuppen E; van Diest PJ
Endocr Relat Cancer; 2019 Oct; 26(10):779-794. PubMed ID: 31340200
[TBL] [Abstract][Full Text] [Related]
53. SULT1A1 gene deletion in BRCA2-associated male breast cancer: a link between genes and environmental exposures?
Palli D; Rizzolo P; Zanna I; Silvestri V; Saieva C; Falchetti M; Navazio AS; Graziano V; Masala G; Bianchi S; Russo A; Tommasi S; Ottini L
J Cell Mol Med; 2013 May; 17(5):605-7. PubMed ID: 23711090
[TBL] [Abstract][Full Text] [Related]
54. Ten novel BRCA1 and BRCA2 mutations in breast and/or ovarian cancer families from northern Germany.
Kiechle M; Gross E; Schwarz-Boeger U; Pfisterer J; Jonat W; Gerber WD; Albacht B; Fischer B; Schlegelberger B; Arnold N
Hum Mutat; 2000 Dec; 16(6):529-30. PubMed ID: 11102986
[TBL] [Abstract][Full Text] [Related]
55. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
Lal G; Liu G; Schmocker B; Kaurah P; Ozcelik H; Narod SA; Redston M; Gallinger S
Cancer Res; 2000 Jan; 60(2):409-16. PubMed ID: 10667595
[TBL] [Abstract][Full Text] [Related]
56. Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation.
Sluiter MD; van Rensburg EJ
Breast Cancer Res Treat; 2011 Jan; 125(2):325-49. PubMed ID: 20232141
[TBL] [Abstract][Full Text] [Related]
57. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.
Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E
Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560
[TBL] [Abstract][Full Text] [Related]
58. Germ line BRCA1 and BRCA2 gene mutations in Turkish breast cancer patients.
Ozdag H; Tez M; Sayek I; Müslümanoglu M; Tarcan O; Içli F; Oztürk M; Ozçelik T
Eur J Cancer; 2000 Oct; 36(16):2076-82. PubMed ID: 11044644
[TBL] [Abstract][Full Text] [Related]
59. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
Díez O; Osorio A; Durán M; Martinez-Ferrandis JI; de la Hoya M; Salazar R; Vega A; Campos B; Rodríguez-López R; Velasco E; Chaves J; Díaz-Rubio E; Jesús Cruz J; Torres M; Esteban E; Cervantes A; Alonso C; San Román JM; González-Sarmiento R; Miner C; Carracedo A; Eugenia Armengod M; Caldés T; Benítez J; Baiget M
Hum Mutat; 2003 Oct; 22(4):301-12. PubMed ID: 12955716
[TBL] [Abstract][Full Text] [Related]
60. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
